博锐生物递表港交所 2025前九月收入约13.79亿元

Core Viewpoint - Zhejiang Borui Biopharmaceutical Co., Ltd. has submitted a listing application to the Hong Kong Stock Exchange, aiming to provide comprehensive immunotherapy solutions for patients with autoimmune and inflammatory diseases, as well as tumor immunology diseases [1] Group 1: Company Overview - Borui Biopharmaceutical is an integrated biopharmaceutical company focusing on immunotherapy, which aims to address diseases where immune dysregulation plays a critical role [1] - The company ranks first among Chinese pharmaceutical companies in revenue from biopharmaceuticals for autoimmune diseases for two consecutive years starting in 2023, according to Frost & Sullivan [1] Group 2: Product Portfolio - The innovative product lineup includes the first-in-class and best-in-class IL-17A/F inhibitor Beijiele® (Bicizumab), the first and only innovative CD20 monoclonal antibody Anruixi (Zebetomab), and BR2251, a potential first-in-class gout drug with a differentiated mechanism of action [2] - These cornerstone immunology products provide a solid foundation for the company's growth and enable the transformation of treatment models for various autoimmune diseases and oncology indications in China [2] Group 3: Financial Performance - For the fiscal years ending September 30, 2023, 2024, and 2025, the company reported revenues of approximately 1.257 billion yuan, 1.623 billion yuan, and 1.379 billion yuan, respectively [2] - The gross profits for the same periods were approximately 1.033 billion yuan, 1.286 billion yuan, and 1.025 billion yuan, with corresponding gross margins of 82.2%, 79.2%, and 74.4% [2] - The net profits attributable to equity shareholders were approximately 19.05 million yuan, 91.295 million yuan, and 122 million yuan for the respective periods [2]